EGI
AKBA icon

EAM Global Investors’s Akebia Therapeutics AKBA Stock Holding History

EAM Global Investors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-126,280
Closed -$1.72M – 131
2020
Q2 		$1.72M Buy
+126,280
New +$1.31M 0.77% 55
2018
Q1 		– Sell
-53,234
Closed -$792K – 138
2017
Q4 		$792K Buy
+53,234
New +$883K 0.41% 115

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EAM Global Investors's AKBA Position: Q3 2020 in Review

EAM Global Investors sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 126,280 shares — an estimated $1.72M sold.

EAM Global Investors first reported a position in AKBA in Q4 2017 and held it in 2 quarters. The position peaked at $1.72M in Q2 2020. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

  • EAM Global Investors reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • EAM Global Investors sold 126,280 Akebia Therapeutics shares in Q3 2020, an estimated $1.72M.
  • EAM Global Investors first reported a position in Akebia Therapeutics in Q4 2017 and held it in 2 quarters.
  • EAM Global Investors's Akebia Therapeutics position peaked at $1.72M in Q2 2020.
  • 164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on EAM Global Investors's 13F filing for Q3 2020, filed 13 Nov 2020.